Linking Stage-Specific Plasma Biomarkers to Gray Matter Atrophy in Parkinson Disease

References

1. 1.↵
   1. Braak H,
   2. Del Tredici K,
   3. Rüb U, et al

   . Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 2003;24:197–211 doi:10.1016/s0197-4580(02)00065-9 pmid:12498954

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Burke RE,
   2. Dauer WT,
   3. Vonsattel JP

   . A critical evaluation of the Braak staging scheme for Parkinson’s disease. Ann Neurol 2008;64:485–91 doi:10.1002/ana.21541 pmid:19067353

   CrossRefPubMedWeb of Science
3. 3.↵
   1. Braak H,
   2. Rub U,
   3. Jansen SE, et al

   . Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 2005;64:1404–10 doi:10.1212/01.WNL.0000158422.41380.82 pmid:15851731

   CrossRefPubMed
4. 4.↵
   1. Irwin DJ,
   2. White MT,
   3. Toledo JB, et al

   . Neuropathologic substrates of Parkinson disease dementia. Ann Neurol 2012;72:587–98 doi:10.1002/ana.23659 pmid:23037886

   CrossRefPubMed
5. 5.↵
   1. Gerhard A,
   2. Pavese N,
   3. Hotton G, et al

   . In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson’s disease. Neurobiol Dis 2006;21:404–12 doi:10.1016/j.nbd.2005.08.002 pmid:16182554

   CrossRefPubMedWeb of Science
6. 6.↵
   1. Paola D,
   2. Domenicotti C,
   3. Nitti M, et al

   . Oxidative stress induces increase in intracellular amyloid beta-protein production and selective activation of betaI and betaII PKCs in NT2 cells. Biochem Biophys Res Commun 2000;268:642–46 doi:10.1006/bbrc.2000.2164 pmid:10679257

   CrossRefPubMedWeb of Science
7. 7.↵
   1. Petrou M,
   2. Dwamena BA,
   3. Foerster BR, et al

   . Amyloid deposition in Parkinson's disease and cognitive impairment: a systematic review. Mov Disord 2015;30:928–35 doi:10.1002/mds.26191 pmid:25879534

   CrossRefPubMed
8. 8.↵
   1. Kotzbauer PT,
   2. Cairns NJ,
   3. Campbell MC, et al

   . Pathologic accumulation of alpha-synuclein and Abeta in Parkinson disease patients with dementia. Arch Neurol 2012;69:1326–31 doi:10.1001/archneurol.2012.1608 pmid:22825369

   CrossRefPubMedWeb of Science
9. 9.↵
   1. Mollenhauer B,
   2. Locascio JJ,
   3. Schulz-Schaeffer W, et al

   . α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 2011;10:230–40 doi:10.1016/S1474-4422(11)70014-X pmid:21317042

   CrossRefPubMedWeb of Science
10. 10.↵
    1. Shi M,
    2. Liu C,
    3. Cook TJ, et al

    . Plasma exosomal alpha-synuclein is likely CNS-derived and increased in Parkinson’s disease. Acta Neuropathol 2014;128:639–50 doi:10.1007/s00401-014-1314-y pmid:24997849

    CrossRefPubMed
11. 11.↵
    1. Yang SY,
    2. Chiu MJ,
    3. Lin CH, et al

    . Development of an ultra-high sensitive immunoassay with plasma biomarker for differentiating Parkinson disease dementia from Parkinson disease using antibody functionalized magnetic nanoparticles. J Nanobiotechnology 2016;14:41 doi:10.1186/s12951-016-0198-5 pmid:27278241

    CrossRefPubMed
12. 12.↵
    1. Siderowf A,
    2. Xie SX,
    3. Hurtig H, et al

    . CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease. Neurology 2010;75:1055–61 doi:10.1212/WNL.0b013e3181f39a78 pmid:20720189

    Abstract/FREE Full Text
13. 13.↵
    1. Kang JH,
    2. Irwin DJ,
    3. Chen-Plotkin AS, et al

    . Parkinson’s Progression Markers Initiative. Association of cerebrospinal fluid beta-amyloid 1-42, T-tau, P-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol 2013;70:1277–87 doi:10.1001/jamaneurol.2013.3861 pmid:23979011

    CrossRefPubMed
14. 14.↵
    1. Atik A,
    2. Stewart T,
    3. Zhang J

    . α-synuclein as a biomarker for Parkinson’s disease. Brain Pathol 2016;26:410–18 doi:10.1111/bpa.12370 pmid:26940058

    CrossRefPubMed
15. 15.↵
    1. Yang CC,
    2. Yang SY,
    3. Chieh JJ, et al

    . Biofunctionalized magnetic nanoparticles for specifically detecting biomarkers of Alzheimer’s disease in vitro. ACS Chem Neurosci 2011;2:500–505 doi:10.1021/cn200028j pmid:22860173

    CrossRefPubMed
16. 16.↵
    1. Chiu MJ,
    2. Chen YF,
    3. Chen TF, et al

    . Plasma tau as a window to the brain-negative associations with brain volume and memory function in mild cognitive impairment and early Alzheimer’s disease. Hum Brain Mapp 2014;35:3132–42 doi:10.1002/hbm.22390 pmid:24129926

    CrossRefPubMed
17. 17.↵
    1. Chiu MJ,
    2. Yang SY,
    3. Horng HE, et al

    . Combined plasma biomarkers for diagnosing mild cognition impairment and Alzheimer’s disease. ACS Chem Neurosci 2013;4:1530–36 doi:10.1021/cn400129p pmid:24090201

    CrossRefPubMed
18. 18.↵
    1. Lin CH,
    2. Yang SY,
    3. Horng HE, et al

    . Plasma α-synuclein predicts cognitive decline in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2017;88:818–24 doi:10.1136/jnnp-2016-314857 pmid:28550072

    Abstract/FREE Full Text
19. 19.↵
    1. Makin S

    . Pathology: the prion principle. Nature 2016;538:S13–16 doi:10.1038/538S13a pmid:27783578

    CrossRefPubMed
20. 20.↵
    1. Pavlov VA,
    2. Tracey KJ

    . Neural circuitry and immunity. Immunol Res 2015;63:38–57 doi:10.1007/s12026-015-8718-1 pmid:26512000

    CrossRefPubMed
21. 21.↵
    1. Hughes AJ,
    2. Daniel SE,
    3. Kilford L, et al

    . Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181–84 doi:10.1136/jnnp.55.3.181 pmid:1564476

    Abstract/FREE Full Text
22. 22.↵
    1. Gasser T,
    2. Bressman S,
    3. Durr A, et al

    . State of the art review: molecular diagnosis of inherited movement disorders: Movement Disorders Society Task Force on molecular diagnosis. Mov Disord 2003;18:3–18 doi:10.1002/mds.10338 pmid:12518296

    CrossRefPubMed
23. 23.↵
    1. Goetz CG,
    2. Poewe W,
    3. Rascol O, et al

    . Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations of the Movement Disorder Society Task Force on rating scales for Parkinson’s disease. Mov Disord 2004;19:1020–28 doi:10.1002/mds.20213 pmid:15372591

    CrossRefPubMedWeb of Science
24. 24.↵
    1. Bjornestad A,
    2. Tysnes OB,
    3. Larsen JP, et al

    . Reliability of three disability scales for detection of independence loss in Parkinson's disease. Parkinsons Dis 2016;2016:1941034 doi:10.1155/2016/1941034 pmid:27213080

    CrossRefPubMed
25. 25.↵
    1. Folstein MF,
    2. Folstein SE,
    3. McHugh PR

    . “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–98 doi:10.1016/0022-3956(75)90026-6 pmid:1202204

    CrossRefPubMedWeb of Science
26. 26.↵
    1. Chang CC,
    2. Liu JS,
    3. Chang YY, et al

    . (99m)Tc-ethyl cysteinate dimer brain SPECT findings in early stage of dementia with Lewy bodies and Parkinson’s disease patients: a correlation with neuropsychological tests. Eur J Neurol 2008;15:61–66 doi:10.1111/j.1468-1331.2007.02001.x pmid:18042240

    CrossRefPubMed
27. 27.↵
    1. Yang SY,
    2. Chiu MJ,
    3. Chen TF, et al

    . Analytical performance of reagent for assaying tau protein in human plasma and feasibility study screening neurodegenerative diseases. Sci Rep 2017;7:9304 doi:10.1038/s41598-017-09009-3 pmid:28839167

    CrossRefPubMed
28. 28.↵
    1. Lin CH,
    2. Yang SY,
    3. Horng HE, et al

    . Plasma biomarkers differentiate parkinson's disease from atypical parkinsonism syndromes. Front Aging Neurosci 2018;10:123 doi:10.3389/fnagi.2018.00123 pmid:29755341

    CrossRefPubMed
29. 29.↵
    1. Wang HC,
    2. Yang TM,
    3. Lin WC, et al

    . The value of serial plasma and cerebrospinal fluid nuclear and mitochondrial deoxyribonucleic acid levels in aneurysmal subarachnoid hemorrhage. J Neurosurg 2013;118:13–19 doi:10.3171/2012.8.JNS112093 pmid:23020765

    CrossRefPubMed
30. 30.↵
    1. Zhang Y,
    2. Cabilio P

    . A generalized Jonckheere test against ordered alternatives for repeated measures in randomized blocks. Stat Med 2013;32:1635–45 doi:10.1002/sim.5606 pmid:22941791

    CrossRefPubMed
31. 31.↵
    1. Pernet CR,
    2. Wilcox R,
    3. Rousselet GA

    . Robust correlation analyses: false positive and power validation using a new open source Matlab toolbox. Front Psychol 2012;3:606 doi:10.3389/fpsyg.2012.00606 pmid:23335907

    CrossRefPubMed
32. 32.↵
    1. Magdalinou N,
    2. Lees AJ,
    3. Zetterberg H

    . Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions. J Neurol Neurosurg Psychiatry 2014;85:1065–75 doi:10.1136/jnnp-2013-307539 pmid:24691581

    Abstract/FREE Full Text
33. 33.↵
    1. Compta Y,
    2. Pereira JB,
    3. Rios J, et al

    . Combined dementia-risk biomarkers in Parkinson’s disease: a prospective longitudinal study. Parkinsonism Rel Disord 2013;19:717–24 doi:10.1016/j.parkreldis.2013.03.009 pmid:23643469

    CrossRefPubMed
34. 34.↵
    1. Jellinger KA,
    2. Seppi K,
    3. Wenning GK, et al

    . Impact of coexistent Alzheimer pathology on the natural history of Parkinson’s disease. J Neural Transm (Vienna) 2002;109:329–39 doi:10.1007/s007020200027 pmid:11956955

    CrossRefPubMed
35. 35.↵
    1. Zou K,
    2. Gong JS,
    3. Yanagisawa K, et al

    . A novel function of monomeric amyloid beta-protein serving as an antioxidant molecule against metal-induced oxidative damage. J Neurosci 2002;22:4833–41 pmid:12077180

    Abstract/FREE Full Text
36. 36.↵
    1. Zou K,
    2. Kim D,
    3. Kakio A, et al

    . Amyloid beta-protein (Abeta)1-40 protects neurons from damage induced by Abeta1-42 in culture and in rat brain. J Neurochem 2003;87:609–19 doi:10.1046/j.1471-4159.2003.02018.x pmid:14535944

    CrossRefPubMedWeb of Science
37. 37.↵
    1. Uribe C,
    2. Segura B,
    3. Baggio HC, et al

    . Cortical atrophy patterns in early Parkinson’s disease patients using hierarchical cluster analysis. Parkinsonism Relat Disord 2018;50:3–9 doi:10.1016/j.parkreldis.2018.02.006 pmid:29449187

    CrossRefPubMed
38. 38.↵
    1. O’Callaghan C,
    2. Hornberger M,
    3. Balsters JH, et al

    . Cerebellar atrophy in Parkinson’s disease and its implication for network connectivity. Brain 2016;139:845–55 doi:10.1093/brain/awv399 pmid:26794597

    CrossRefPubMed
39. 39.↵
    1. Roy R,
    2. Niccolini F,
    3. Pagano G, et al

    . Cholinergic imaging in dementia spectrum disorders. Eur J Nucl Med Mol Imaging 2016;43:1376–86 doi:10.1007/s00259-016-3349-x pmid:26984612

    CrossRefPubMed
40. 40.↵
    1. Jagust W

    . Imaging the evolution and pathophysiology of Alzheimer disease. Nat Rev Neurosci 2018;19:687–700 doi:10.1038/s41583-018-0067-3 pmid:30266970

    CrossRefPubMed
41. 41.↵
    1. Gomperts SN,
    2. Locascio JJ,
    3. Makaretz SJ, et al

    . Tau positron emission tomographic imaging in the Lewy body diseases. JAMA Neurol 2016;73:1334–41 doi:10.1001/jamaneurol.2016.3338 pmid:27654968

    CrossRefPubMed
42. 42.↵
    1. Chen YS,
    2. Chen MH,
    3. Lu CH, et al

    . Associations among cognitive functions, plasma DNA, and white matter integrity in patients with early-onset Parkinson’s Disease. Front Neurosci 2017;11:9 doi:10.3389/fnins.2017.00009 pmid:28174514

    CrossRefPubMed
43. 43.↵
    1. Alibhai J,
    2. Blanco RA,
    3. Barria MA, et al

    . Distribution of misfolded prion protein seeding activity alone does not predict regions of neurodegeneration. PLoS Biol 2016;14:e1002579 doi:10.1371/journal.pbio.1002579 pmid:27880767

    CrossRefPubMed